Venclexta is named as an intervention in 28 current clinical trials in our China, Israel, Australia, USA, Germany, France, UK, Spain, Belgium, Poland, Italy, Netherlands, Denmark, Canada, South Korea, Sweden, Austria, Czechia, Japan, Taiwan, Ireland, Brazil, Turkey, Portugal, Mexico and Egypt registers. 13 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Dana-Farber Cancer Institute (4). The most-studied condition is Acute Myeloid Leukemia.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Acute Myeloid Leukemia | 6 |
| Chronic Lymphocytic Leukemia | 5 |
| Chronic Lymphocytic Leukemia (CLL) | 3 |
| Small Lymphocytic Lymphoma | 2 |
| Myelodysplastic Syndromes | 2 |
| Small Lymphocytic Lymphoma (SLL) | 2 |
| Mantle Cell Lymphoma | 2 |
| Multiple Myeloma | 1 |
| Non-Hodgkin's Lymphoma | 1 |
| Myelodysplastic Syndrome/Neoplasm | 1 |
| Chronic Myelomonocytic Leukemia | 1 |
| Myelodysplastic Syndrome (MDS) | 1 |
| Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | 1 |
| Hematologic Malignancies | 1 |
| AML, Adult | 1 |
| Chemotherapy Effect | 1 |
| Acute Promyelocytic Leukemia (APL) | 1 |
| Acute Myeloid Leukemia (AML) in Remission | 1 |
| Relapsed/Refractory AML | 1 |
| AML | 1 |
| MDS | 1 |
| CLL/SLL | 1 |
| CLL | 1 |
| Mantle Cell Lymphoma Refractory | 1 |
| Follicular Lymphoma | 1 |
| Richter Syndrome | 1 |
| Myeloid Malignancy | 1 |
| Myelofibrosis | 1 |
| Waldenstrom Macroglobulinemia | 1 |
| Refractory Lymphoma | 1 |
+ 5 more sponsors in the trial list above.
A trial with sites in more than one country appears in each of those registers.
28 current trials in our China, Israel, Australia, USA, Germany, France, UK, Spain, Belgium, Poland, Italy, Netherlands, Denmark, Canada, South Korea, Sweden, Austria, Czechia, Japan, Taiwan, Ireland, Brazil, Turkey, Portugal, Mexico and Egypt registers name Venclexta (also registered as Interleukin-11 (IL-11)) as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 13 of the 28 trials are recruiting: 5 with sites in China, 4 with sites in Israel, 2 with sites in Australia, 4 with sites in USA, 5 with sites in Germany, 3 with sites in France, 3 with sites in UK, 3 with sites in Spain, 2 with sites in Belgium, 3 with sites in Poland, 3 with sites in Italy, 3 with sites in Netherlands, 3 with sites in Denmark, 2 with sites in Canada, 2 with sites in South Korea, 2 with sites in Sweden, 1 with sites in Austria, 2 with sites in Czechia, 1 with sites in Japan, 1 with sites in Ireland, 1 with sites in Brazil and 1 with sites in Egypt. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Dana-Farber Cancer Institute (4), AbbVie (3), The First Affiliated Hospital of Soochow University (2) and Peter MacCallum Cancer Centre, Australia (2), among 20 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Yes. 2 trials in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Venclexta works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records โ it is not written from memory, and nothing here describes how Venclexta works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Venclexta (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.